生脉注射液配合介入化疗治疗非小细胞肺癌前后VEGF水平变化

The VEGF levels after pulse-activating ingection combined with interventional chemotherapy for non-small cell lung cancer

目的:观察生脉注射液加介入化疗治疗非小细胞肺癌(NSCLC)的疗效及治疗前后血清VEGF与EGF水平变化。方法:59例NSCLC随机分为两组,治疗组为生脉注射液加介入化疗治疗,对照组为单纯介入化疗。结果:治疗组(31例)与对照组(28例)的近期客观疗效分别为67.2%和53.3%,临床症状改善率分别为69.5%和41.8%,生存质量改善率分别为55.9%和31.7%。治疗组治疗前后血清VEGF分别为(241.90±46.47)、(137.56±36.53)。对照组治疗前后VEGF水平分别为(239.75±36.59)、(192.21±40.33)。经统计学处理,两组治疗前后在血清VEGF水平变化、临床症状及存质量改善方面差异有统计学意义(P<0.05)。结论:生脉注射液对接受介入化疗的NSCL患者,有助于临床症状的进一步改善和生存质量的提高。

Objective： To observe medical effects of Shengmai injecta plus interventional chemotherapy for non small cell lung cancer （NSCLC） and to observe the changes of serum VEGF and EGF level between pretreatment and posttreatment. Method： 59 NSCLC patients were randomly divided into two groups. Results： Recent clinical effects of the treatment group （31 patients） and the control group （28 patients） respectively were 67.2% and 53.3%, clinical improvement rate respectively were 69.5%o and 41.8%, improving rate of life qualities respectively were 55.9% and 31.7%. Serum VEGF level of treatment group between pretreatment and posttreatment respective were （241.90± 46.74） and 1（37.56±36.53）. Serum VEGF of control group between pretreatment and posttreatment respective were （239. 75 ± 36. 95） and （192. 21±40. 33）. After statistics processing, the differences had statistical significance between two groups in the change of serum VEGF level, relief of clinical symptoms, andimpeovement of life qualities （P 〈0.05）. Conclusion： Shengmai injecta helps to relieve the clinical symptoms and to improve the quality of life for NSCL patients accepting interventional chemotherapy.